Venture capital investment in life sciences hits record high
The life sciences industry is experiencing record levels of investment across both businesses and associated real estate, with the pandemic having highlighted both the sector’s importance and its resilience as an asset class, reported JLL.
Global venture capital, a key driver of life science company growth, has been rising rapidly throughout 2021, already surpassing 2019 full-year total of $63.3 billion. This growth is set to continue, with no signs of slowing, as much of the capital raised by investors is yet to be deployed.
In Europe, the United Kingdom is by far the dominant market, accounting for more than double the venture capital raised in Germany, the second-largest European market. In the United Kingdom, record levels of venture capital have been raised during the past three months, with £1.9 billion (€2.2 billion/$2.6 billion) raised between June 1 and Aug. 26, an astonishing volume of investment that puts the U.K. total to £4.25 billion (€4.9 billion